Search research articles
Contact Us
Filters
Showing results (21-30 of 72) with videos related to
Page
of 8
Sort By:
Health Policy (Amsterdam, Netherlands)
|
May 22, 2012
Calculating an intervention's (cost-)effectiveness for the real-world target population: the potential of combining strengths of both RCTs and observational data
Mattias Neyt, Irina Cleemput, Nancy Thiry, et al.
Pharmacoeconomics
|
January 11, 2025
Projections of Public Spending on Pharmaceuticals: A Review of Methods
Irina Odnoletkova, Patrice X Chalon, Stephan Devriese, et al.
International Journal of Technology Assessment in Health Care
|
September 20, 2012
Similarities and differences between five European drug reimbursement systems
Margreet Franken, Maïté le Polain, Irina Cleemput, et al.
Pharmacoeconomics
|
December 21, 2004
The economic implications of non-adherence after renal transplantation
Irina Cleemput, Katrien Kesteloot, Yves Vanrenterghem, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
November 11, 2009
Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests
Irina Cleemput, Philippe van Wilder, Michel Huybrechts, et al.
Acta Gastro-Enterologica Belgica
|
November 5, 2005
Noncompliance with immunosuppressive regimen in organ transplantation: is it worth worrying about?
Ariane Desmyttere, Fabienne Dobbels, Irina Cleemput, et al.
BJU International
|
August 18, 2005
The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis
Lieven Annemans, Irina Cleemput, Mark Lamotte, et al.
Journal of Medical Economics
|
May 21, 2010
Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013
Alain Denis, Lut Mergaert, Christel Fostier, et al.
Applied Health Economics and Health Policy
|
September 1, 2010
Issues surrounding orphan disease and orphan drug policies in Europe
Alain Denis, Lut Mergaert, Christel Fostier, et al.
Health Policy (Amsterdam, Netherlands)
|
August 31, 2010
A comparative study of European rare disease and orphan drug markets
Alain Denis, Lut Mergaert, Christel Fostier, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 72) with videos related to
Sort By:
Page
of 8
Health Policy (Amsterdam, Netherlands)
|
May 22, 2012
Calculating an intervention's (cost-)effectiveness for the real-world target population: the potential of combining strengths of both RCTs and observational data
Mattias Neyt, Irina Cleemput, Nancy Thiry, et al.
Pharmacoeconomics
|
January 11, 2025
Projections of Public Spending on Pharmaceuticals: A Review of Methods
Irina Odnoletkova, Patrice X Chalon, Stephan Devriese, et al.
International Journal of Technology Assessment in Health Care
|
September 20, 2012
Similarities and differences between five European drug reimbursement systems
Margreet Franken, Maïté le Polain, Irina Cleemput, et al.
Pharmacoeconomics
|
December 21, 2004
The economic implications of non-adherence after renal transplantation
Irina Cleemput, Katrien Kesteloot, Yves Vanrenterghem, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
November 11, 2009
Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests
Irina Cleemput, Philippe van Wilder, Michel Huybrechts, et al.
Acta Gastro-Enterologica Belgica
|
November 5, 2005
Noncompliance with immunosuppressive regimen in organ transplantation: is it worth worrying about?
Ariane Desmyttere, Fabienne Dobbels, Irina Cleemput, et al.
BJU International
|
August 18, 2005
The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis
Lieven Annemans, Irina Cleemput, Mark Lamotte, et al.
Journal of Medical Economics
|
May 21, 2010
Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013
Alain Denis, Lut Mergaert, Christel Fostier, et al.
Applied Health Economics and Health Policy
|
September 1, 2010
Issues surrounding orphan disease and orphan drug policies in Europe
Alain Denis, Lut Mergaert, Christel Fostier, et al.
Health Policy (Amsterdam, Netherlands)
|
August 31, 2010
A comparative study of European rare disease and orphan drug markets
Alain Denis, Lut Mergaert, Christel Fostier, et al.
Page
of 8